Voyager Therapeutics: Promising Future Prospects with Strong Financial Position and Innovative Pipeline

Analyst Yanan Zhu of Wells Fargo maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), retaining the price target of $10.00.

Yanan Zhu has given his Buy rating due to a combination of factors that highlight Voyager Therapeutics’ promising future prospects. The company’s tau targeting programs are progressing well, with anticipated data from Merck’s anti-tau mAb MK-2214 expected to act as a catalyst in the third quarter of 2025. Additionally, Voyager’s collaboration with Neurocrine Biosciences (NBIX) is on track, with potential for significant milestone payments in the near term, which could further strengthen the company’s financial position.
Voyager’s financial health is also a contributing factor to the Buy rating. Despite reporting a net loss per share that was slightly below consensus expectations, the company maintains a robust cash position that is projected to support operations into mid-2027. This financial stability, combined with the potential for milestone payments from partnered programs, provides a solid foundation for future growth. Furthermore, the ongoing development of innovative therapies, such as the VY1706 vectorized tau siRNA for Alzheimer’s disease, underscores Voyager’s commitment to advancing its pipeline and achieving clinical milestones.

VYGR’s price has also changed dramatically for the past six months – from $7.280 to $3.250, which is a -55.36% drop .